Meeting
2021 Gastrointestinal Cancers Symposium
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Authors
Jeffrey Sum Lung Wong
University of Hong Kong, Hong Kong, China
Jeffrey Sum Lung Wong , Gin Wai Kwok , Vikki Tang , Bryan Li , Roland Ching-Yu Leung , Joanne Wing Yan Chiu , Ka Wing Ma , Wong-Hoi She , Wing Yan Josephine Tsang , Tan To Cheung , Thomas Yau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 330)
DOI
10.1200/JCO.2021.39.3_suppl.330
Abstract #
330
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2020 Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
First Author: Aiwu Ruth He